SCHEMBL26511014

SCHEMBL26511014

CCOC(=O)CN(CC)CN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
ALDH1A1 P00352 5/20 0.46
TRPA1 O75762 1/20 0.46
CYP1A2 P05177 1/20 0.45
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SOAT1 P35610 1/20 0.34
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
OPRK1 P41145 1/20 0.33
GSK3A P49840 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708934 0.87 CA12 (0.57) CA12CA1CA2CA9ALDH1A1
SCHEMBL264830 0.87 CA12 (0.57) CA12CA1CA2CA9ALDH1A1
Hydrochloric Acid SCHEMBL27973018 0.85 CA12 (0.55) CA12CA1CA2CA9ALDH1A1
SCHEMBL23775491 0.84 CA12 (0.47) CA12CA1CA2CA9ALDH1A1
SCHEMBL65107 0.82 CA12 (0.61) CA12CA1CA2CA9ALDH1A1
SCHEMBL26017636 0.79 CA1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL5201822 0.79 CA1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL5851951 0.78 CA1 (0.57) CA12CA1CA2CA9ALDH1A1
Hydrochloric Acid SCHEMBL5201814 0.78 CA1 (0.48) CA12CA1CA2CA9ALDH1A1
Hydrochloric Acid SCHEMBL30622728 0.78 CA12 (0.48) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY MERCK SHARP & DOHME LLC (US) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY ADORA2A, ADORA2B, ADORA1 CA12 1932/4885CA1 2257/4885CA2 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.